ClinVar Miner

Submissions for variant NM_032043.2(BRIP1):c.3331G>C (p.Glu1111Gln) (rs587780248)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000214821 SCV000273518 uncertain significance Hereditary cancer-predisposing syndrome 2016-11-09 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient or conflicting evidence,In silico models in agreement (benign)
Color RCV000214821 SCV000684257 uncertain significance Hereditary cancer-predisposing syndrome 2018-08-27 criteria provided, single submitter clinical testing
Counsyl RCV000409119 SCV000490027 uncertain significance Fanconi anemia, complementation group J 2016-10-05 criteria provided, single submitter clinical testing
Counsyl RCV000410336 SCV000490028 uncertain significance Neoplasm of ovary 2016-10-05 criteria provided, single submitter clinical testing
GeneDx RCV000116155 SCV000150064 uncertain significance not provided 2018-09-21 criteria provided, single submitter clinical testing This variant is denoted BRIP1 c.3331G>C at the cDNA level, p.Glu1111Gln (E1111Q) at the protein level, and results in the change of a Glutamic Acid to a Glutamine (GAA>CAA). This variant was observed in at least two individuals, one with breast and the other with ovarian cancer (Lu 2015, Ramus 2015). BRIP1 Glu1111Gln was not observed at a significant allele frequency in large population cohorts (Lek 2016). This variant is not located in a known functional domain. In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function. Based on currently available evidence, it is unclear whether BRIP1 Glu1111Gln is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Invitae RCV000204181 SCV000259653 uncertain significance Familial cancer of breast; Fanconi anemia, complementation group J 2018-10-02 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid with glutamine at codon 1111 of the BRIP1 protein (p.Glu1111Gln). The glutamic acid residue is weakly conserved and there is a small physicochemical difference between glutamic acid and glutamine. This variant is present in population databases (rs587780248, ExAC 0.003%). This variant has been reported in individuals affected with ovarian and breast cancer (PMID: 26315354, 26689913). ClinVar contains an entry for this variant (Variation ID: 128186). Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.